Statin use and the risk of colorectal cancer: A population-based case-control study

Table 1 Demographic characteristics of colorectal cancer cases and controls

Variable	Cases (n = 1156)	Controls (n = 4624)	Odds ratio (95% CI)
Age, yr (mean ± SD)	68.34 ± 10.40	69.29 ± 10.40	-
Female (%)	447 (38.67)	1788 (38.67)	-
No. of hospitalizations	0.29 ± 0.93	0.26 ± 0.74	P = 0.23
Diabetes (%)	422 (36.51)	1560 (33.74)	1.13 (0.99-1.29)
Cholecystectomy (%)	21 (1.82)	105 (2.27)	0.80 (0.50-1.28)
Liver disease (%)	422 (36.51)	1861 (40.25)	0.85 (0.75-0.98)
Colorectal polyps (%)	56 (4.84)	76 (1.64)	3.05 (2.14-4.33)
Inflammatory bowel disease (%)	82 (7.09)	315 (6.81)	1.04 (0.81-1.34)
Colonoscopy (%)	153 (13.24)	42 (0.91)	16.64 (11.75-23.57)
FOBT (%)	152 (13.15)	216 (4.67)	3.09 (2.48-3.84)
NSAID (%)	636 (55.02)	2767 (59.84)	0.82 (0.72-0.93)
Use of other lipid-lowering drugs (%)	31 (2.68)	180 (3.89)	0.68 (0.46-1.00)

FOBT: Fecal occult blood testing; NSAID: Non-steroidal anti-inflammatory drug; CI: Confidence interval.

Table 2 Associations between statin use and colorectal cancer risk in a population-based case-control study, Taiwan, 2005-2008

	Cases (n)/controls (n)	Crude OR (95% CI)	Adjusted OR (95% CI)1
Overall
No statin use	914/3727	1.00	1.00
Any statin use	242/897	1.10 (0.94-1.30)	1.09 (0.91-1.30)
Cumulative use
0	914/3727	1.00	1.00
1-105 DDD	112/451	1.02 (0.82-1.27)	0.99 (0.78-1.27)
106-298.66 DDD	60/221	1.11 (0.83-1.49)	1.07 (0.78-1.49)
> 298.66 DDD	70/225	1.27 (0.96-1.68)	1.30 (0.96-1.75)

OR: Odds ratio; CI: Confidence interval; DDD: Defined daily dose.

¹Adjusted for matching variable, diabetes, number of hospitalizations, cholecystectomy, liver disease, colorectal polyps, inflammatory bowel disease, colonoscopy, fecal occult blood testing, non-steroidal anti-inflammatory drugs and use of other lipid-lowering drugs.